Family · Pharmaceutical analytical standards
Ranolazine
A piperazine-derived antianginal, approved in the United States in 2006 and in Europe in 2008 for chronic stable angina: it inhibits the late sodium current in heart cells, preventing calcium overload. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?Unlike many antianginals, its action does not depend on slowing the pulse or lowering blood pressure: in studies these fell on average by less than 2 beats per minute and less than 3 mmHg.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
